SARS-CoV-2 Rebound Rate Similar With, Without Oral Antivirals
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 22, 2023 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rebound occurs at a similar rate for those receiving and not receiving oral antiviral treatment and for those receiving nirmatrelvir/ritonavir or placebo, according to research published in the Dec. 22 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Dallas J. Smith, Pharm.D., from the CDC in Atlanta, and colleagues reviewed SARS-CoV-2 rebound studies published during Feb. 1, 2020, to Nov. 29, 2023, to enhance current understanding of rebound. Seven studies met the inclusion criteria: one randomized trial and six observational studies, which compared rebound for those receiving and not receiving antiviral treatment. The researchers observed no significant differences in rebound rates for those receiving versus not receiving treatment in four studies, including the randomized trial. Outpatients who experienced rebound had no hospitalizations or deaths reported.
Patrick R. Harrington, Ph.D., from the U.S. Food and Drug Administration in Silver Spring, Maryland, and colleagues examined viral RNA shedding from two phase 2/3 placebo-controlled, randomized trials of nirmatrelvir/ritonavir to examine the role of treatment in COVID-19 rebound. The researchers found that patients receiving nirmatrelvir/ritonavir or placebo had similar rates of SARS-CoV-2 RNA shedding based on nasopharyngeal viral RNA levels from day 5 (end of treatment) to day 10 or day 14. Viral RNA rebound occurred in 6.4 to 8.4 percent of nirmatrelvir/ritonavir recipients and 5.9 to 6.5 percent of placebo recipients among those with a virologic response through day 5.
"These findings support FDA's determination of safety and efficacy of nirmatrelvir/ritonavir in eligible patients at high risk for severe COVID-19," Harrington and colleagues write.
Abstract/Full Text - Harrington
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Further Support and Information on COVID-19
Read this next
Elevated BMI Linked to Postacute Sequelae of SARS-CoV-2 in Children
WEDNESDAY, Oct. 30, 2024 -- For children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, elevated body mass index (BMI) is associated with an...
IDSA: Vaccination Less Likely With Increasing Social Vulnerability, Black Race
FRIDAY, Oct. 18, 2024 -- Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV) is less likely with an...
In Utero Exposure to COVID-19 Not Tied to Later Neurodevelopmental Issues
THURSDAY, Oct. 17, 2024 -- Exposure to maternal COVID-19 is not associated with abnormal neurodevelopmental screening results through 24 months postpartum, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.